These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 14560494)

  • 21. Neuroleptic dysphoria: revisiting the concept 50 years later.
    Awad AG; Voruganti LN
    Acta Psychiatr Scand Suppl; 2005; (427):6-13. PubMed ID: 15877718
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of a managed behavioral health carve-out on quality of care for medicaid patients diagnosed as having schizophrenia.
    Busch AB; Frank RG; Lehman AF
    Arch Gen Psychiatry; 2004 May; 61(5):442-8. PubMed ID: 15123488
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical correlates of antipsychotic polytherapy in patients with schizophrenia in Singapore.
    Sim K; Su A; Chan YH; Shinfuku N; Kua EH; Tan CH
    Psychiatry Clin Neurosci; 2004 Jun; 58(3):324-9. PubMed ID: 15149301
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A survey of patient satisfaction with and subjective experiences of treatment with antipsychotic medication.
    Gray R; Rofail D; Allen J; Newey T
    J Adv Nurs; 2005 Oct; 52(1):31-7. PubMed ID: 16149978
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The concepts of remission and recovery in schizophrenia.
    Leucht S; Lasser R
    Pharmacopsychiatry; 2006 Sep; 39(5):161-70. PubMed ID: 16944406
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quality of life and subjective well-being during treatment with antipsychotics in out-patients with schizophrenia.
    Wehmeier PM; Kluge M; Schneider E; Schacht A; Wagner T; Schreiber W
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Apr; 31(3):703-12. PubMed ID: 17289237
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antipsychotic medication use patterns and associated costs of care for individuals with schizophrenia.
    Loosbrock DL; Zhao Z; Johnstone BM; Morris LS
    J Ment Health Policy Econ; 2003 Jun; 6(2):67-75. PubMed ID: 14578539
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Relationships between positive or negative early subjective response to antipsychotics and demographic and clinical variables in the group of patients with schizophrenia].
    Murawiec S
    Psychiatr Pol; 2005; 39(6):1185-98. PubMed ID: 16526184
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Pharmacotherapy in schizophrenia--comparison of second generation antipsychotic agents].
    Melamed Y; Finkel B; Barak Y; Zipris P; Oyffe I; Weizman A; Bleich A
    Harefuah; 2005 Apr; 144(4):285-90, 301. PubMed ID: 15889614
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A clinical case series of switching from antipsychotic polypharmacy to monotherapy with a second-generation agent on patients with chronic schizophrenia.
    Suzuki T; Uchida H; Watanabe K; Yagi G; Kashima H
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Mar; 28(2):361-9. PubMed ID: 14751434
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effectiveness of guideline implementation strategies on improving antipsychotic medication management for schizophrenia.
    Owen RR; Hudson T; Thrush C; Thapa P; Armitage T; Landes RD
    Med Care; 2008 Jul; 46(7):686-91. PubMed ID: 18580387
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The optimal level of dopaminergic neurotransmission].
    de Haan L
    Ned Tijdschr Geneeskd; 2005 Jul; 149(31):1721-2. PubMed ID: 16114285
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of schizophrenia patients: comparing new-generation antipsychotics to each other.
    Fleischhacker WW; Widschwendter CG
    Curr Opin Psychiatry; 2006 Mar; 19(2):128-34. PubMed ID: 16612191
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Paliperidone extended-release tablets for the acute and maintenance treatment of schizophrenia.
    Fowler JA; Bettinger TL; Argo TR
    Clin Ther; 2008 Feb; 30(2):231-48. PubMed ID: 18343262
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Long-acting injectable risperidone: naturalistic study in three hospitals in Aquitaine].
    Raignoux C; Dusouchet T; Bret P; Queuille E; Biscay ML; Caron J; Bret MC
    Encephale; 2007 Dec; 33(6):973-81. PubMed ID: 18789790
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis.
    Kuroki T; Nagao N; Nakahara T
    Prog Brain Res; 2008; 172():199-212. PubMed ID: 18772034
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Another view of the history of antipsychotic drug discovery and development.
    Carpenter WT; Davis JM
    Mol Psychiatry; 2012 Dec; 17(12):1168-73. PubMed ID: 22889923
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Research methodology and the pharmacotherapy of the chronic schizophrenias.
    Ban TA; Guy W; Wilson WH
    Psychopharmacol Bull; 1986; 22(1):36-41. PubMed ID: 2873618
    [No Abstract]   [Full Text] [Related]  

  • 39. The introduction of neuroleptics: a psychiatric revolution.
    Cancro R
    Psychiatr Serv; 2000 Mar; 51(3):333-5. PubMed ID: 10686239
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Changes in clinical course and symptomatology of schizophrenia following introduction of pharmacotherapy].
    Murakami K
    Seishin Shinkeigaku Zasshi; 1971 Aug; 73(8):635-49. PubMed ID: 5166836
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.